EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

Evaluation of Novel Isatin–Schiff Base Derivatives: Monoamine Oxidase Inhibition and Antimicrobial Assessment

Marthinus J Jooste iD, Stephanus J Cloete iD, Anél Petzer iD, Jacobus P Petzer iD, Theunis T Cloete iD

ChemMedChem · 2026

DOI: 10.1002/cmdc.70437 ↗

At a glance

Journal article in ChemMedChem, 2026. Written by Marthinus J Jooste and 4 co-authors. Institution: Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, South Africa. Major MEDLINE topics: Isatin, Monoamine Oxidase Inhibitors, Monoamine Oxidase, Anti-Bacterial Agents. 71 references. The full text is freely available (open access, CC BY 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Five novel series of isatin–Schiff base derivatives ( 1a–5e ) were synthesized, and their neuroprotective and anti‐infective potential was evaluated. Their half‐maximal inhibitory concentration (IC 50 ) was determined against both monoamine oxidase A (MAO‐A) and MAO‐B targets for the treatment of depression and Parkinson's disease, respectively. The anti‐infective potential of the synthesized derivatives was evaluated by measuring their IC 50 values against urease, an enzyme utilized by specific pathogenic bacteria as a virulence factor. The minimum inhibitory concentration for each compound was assessed against a panel of human pathogens. Most derivatives had potent in vitro activity against MAO‐A and MAO‐B, even greater than the positive control, isatin. The 4‐chloroisatin substituted series ( 2a – d ) showed exceptional MAO‐A inhibition ( 2d : 0.040 ± 0.002 µM), while the unsubstituted, 5‐, 6‐, and 7‐chloroisatin analogues ( 1a – e , 3a – c , 4a – b , and 5a – e ) demonstrated high potency and selectivity toward MAO‐B, the most active being 5d (0.018 ± 0.003 µM; selectivity index = 15 389). Kinetic analysis confirmed a competitive and reversible mode of inhibition. None of the derivatives showed urease inhibition or significant antibacterial activity. These findings highlight the isatin–Schiff base derivatives as promising agents for potent and selective MAO inhibitors with therapeutic potential for neurodegenerative disorders.

Subjects

MeSH terms (MEDLINE)

IsatinMonoamine Oxidase InhibitorsMonoamine OxidaseAnti-Bacterial AgentsAnti-Infective AgentsHumansStructure-Activity RelationshipSchiff BasesMicrobial Sensitivity TestsMolecular StructureDose-Response Relationship, Drug

Author keywords

Parkinson's diseaseSchiff basedepressionisatinminimum inhibitory concentrationmonoamine oxidaseurease

Substances

IsatinMonoamine Oxidase InhibitorsMonoamine OxidaseSchiff BasesAnti-Bacterial AgentsAnti-Infective Agents

Authors and institutions

  • Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, South Africa.
  • Pharmaceutical Chemistry, School of Pharmacy, North-West University, Potchefstroom, South Africa.

ORCID profiles: Marthinus J Jooste, Stephanus J Cloete, Anél Petzer, Jacobus P Petzer, Theunis T Cloete

Cite

APA

Jooste, M. J., Cloete, S. J., Petzer, A., Petzer, J. P., & Cloete, T. T. (2026). Evaluation of Novel Isatin–Schiff Base Derivatives: Monoamine Oxidase Inhibition and Antimicrobial Assessment. ChemMedChem. https://doi.org/10.1002/cmdc.70437

Vancouver

Jooste MJ, Cloete SJ, Petzer A, Petzer JP, Cloete TT. Evaluation of Novel Isatin–Schiff Base Derivatives: Monoamine Oxidase Inhibition and Antimicrobial Assessment. ChemMedChem. 2026. doi:10.1002/cmdc.70437

BibTeX
@article{Jooste2026,
  author = {Jooste, Marthinus J and Cloete, Stephanus J and Petzer, Anél and Petzer, Jacobus P and Cloete, Theunis T},
  title = {Evaluation of Novel Isatin–Schiff Base Derivatives: Monoamine Oxidase Inhibition and Antimicrobial Assessment},
  journal = {ChemMedChem},
  year = {2026},
  doi = {10.1002/cmdc.70437}
}
Start for free →